Could CSL leadership be asleep at the wheel?, page-2

@Ladytradr

Hey, you've got lots of light bulbs. You're smart and informative. I'm not.

Can I please respond? Thank you...

Wesfarmers have invested in AFI. Yep, it's slow and it's boring and quite frankly, I don't even know if it's a good acquisition?

Retail investors like myself probably invest in WES for income and longer term capital growth. They're kind of like the centre half back of my portfolio. Wesfarmers in most respects, stick to their knitting and it's fair to say that they don't invest in early stage biotechs. As a shareholder, I'm happy with that. If I want to speculate in biotechs. I'll do it myself.

CSL on the other hand is everything that every other ASX listed biotech wants to become. That is - THE NEXT CSL!

Of the ASX listed biotechs, I think there's may be close to a couple hundred with many more that are unlisted. Your post contains highly speculative numbers. Their RP11 trials are currently at phase 1, meaning that PYC are either enrolling or recruiting to populate their trials. But I wont pretend to know what I don't know. CSL have numerous trials ongoing in various stages of the trial cycle. Why would CSL want to invest in an early stage biotech? It's like telling BHP to invest in a minerals explorer who's kicking around a few rocks in the Gibson Desert. As an investor in CSL, I don't expect CSL to speculate in biotechs. I'll do it myself.

But it's this remark that prompted me to respond to your post; "If PYC had the validation and financial support of a leading company like CSL...."

There it is.

Why would they even bother? Probably better to wait for PYC to grind through the trials over the next decade and avoid all of the imminent cap raises and then buy the company outright when there's more certainty around PYC's candidate drug(s). Or maybe not. They're busy with their own portfolio of candidate drugs.

I can see your point. But to post a thread asking if the leadership at CSL are asleep at the wheel in relation to PYC is a little provocative. I see your intent and feel that it might be a little misguided. Ironically (in a way), I've invested in another biotech mid year that is currently at phase 3 trials. That biotech is called Opthea (OPT) and year-to-date, the trajectory of the share price of OPT has almost mirrored that of PYC.

I don't expect CSL to invest in Opthea. Nor will I sell any of my holdings in CSL to fund a purchase in Opthea. I saved the cash and became a share holder when I was able to. I did it myself.